<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 158.4 seconds (2åˆ†38ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 121,525</li>
<li>Output: 3,798</li>
<li>Total: 125,323</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>anthropic/claude-opus-4.5 (Openrouter)</strong>: 
23 calls, 
125,323 tokens 
(121,525 in / 3,798 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-21_07-14-45</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre># Final Assessment
Recurrent platinum-resistant (PFI 56 days) ovarian clear cell carcinoma with hepatic, presacral, and bone metastases; BRCA1/2 negative, HRD negative [@OH2203828 | Genomics], limiting PARPi utility; moderate anemia requires correction before systemic therapy.

# Core Treatment Strategy
- **Initiate non-platinum systemic regimen** per platinum-resistant status classification [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
- **Correct anemia (Hgb 74 g/L)** [@20230103|5600862 | LAB] with transfusion before chemotherapy initiation
- **Obtain PET-CT** for complete metabolic staging to guide treatment planning [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
- **Evaluate clinical trial eligibility** for BL-B01D1 study in recurrent gynecologic malignancies [@trial | 350]; confirm ECOG status and organ function

# Change Triggers
- If MSI-high/TMB-high detected, consider adding checkpoint inhibitor to treatment strategy [@pubmed | 35096598]
- If bone lesions show high fracture risk on orthopedic assessment, initiate bone-modifying agents before systemic therapy</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: nccn_ovariancancer_v3_2025__v00000000, Page 22</div>
<div class='ref-detail-line'>Content: Survivorship)</div>
<div class='ref-detail-line'>Recurrent</div>
<div class='ref-detail-line'>diseaset</div>
<div class='ref-detail-line'>Hormonal...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 11</div>
<div class='ref-detail-line'>Content: cytoreduction</div>
<div class='ref-detail-line'>o Residual ChT toxicity</div>
<div class='ref-detail-line'>o The patientâ€™s...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
<div class='ref-entry'>
<div class='ref-tag'>[@pubmed | 35096598]</div>
<div class='ref-details'>
<div class='ref-detail-line'>PMID: 35096598 | Front Oncol | 2021-01-01</div>
<div class='ref-detail-line'>Title: Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.</div>
<div class='ref-detail-line'>DOI: 10.3389/fonc.2021.798173</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
<div class='ref-entry'>
<div class='ref-tag'>[@trial | 350]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Trial ID: 350</div>
<div class='ref-detail-line'>Name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶</div>
<div class='ref-detail-line'>Rationale: Patient has recurrent/metastatic ovarian clear cell carcinoma (gynecologic malignancy) with prior standard therapy failure (platinum-resistant after 1L), matching the trial&#x27;s inclusion for recurrent/metastatic gynecologic malignancies after standard treatment failure.</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2203828 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2203828 | Date: 2022-04-18</div>
<div class='ref-detail-line'>Content: ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230103|5600862 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230103|5600862 | Date: 2023-01-03</div>
<div class='ref-detail-line'>Content: ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN) PLTåˆ†å¸ƒå®½åº¦ 12 % (PDW) å—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L...</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰æœ¯åç™½ç´«+å¡é“‚åŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡ï¼š2022.8.172022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)MRï¼ˆ2022.07.17ï¼‰ï¼š2022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.10.12ï¼‰ï¼šCA19-9:77.20U/mlâ†‘,CA125:89.60U/mlâ†‘,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(ç»ç»å‰)â†‘,ROMA.:36.67%(ç»ç»å)â†‘ã€‚CTï¼ˆ2022.10.25ï¼‰ï¼šè‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚MRï¼ˆ2022.10.24ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚2022.11.10å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 2.36ï¼Œçº¢ç»†èƒ 3.56ï¼Œè¡€çº¢è›‹ç™½ 97ï¼Œè¡€å°æ¿ 153å¤–é™¢ç”ŸåŒ–ï¼šALPã€€105ï¼ŒNA 136ï¼ŒPAB 1242022.11.30å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 3.46ï¼Œçº¢ç»†èƒ 3.48ï¼Œè¡€çº¢è›‹ç™½ 94ï¼Œè¡€å°æ¿ 1342022.11.17å¤–é™¢è‚¿ç˜¤æŒ‡æ ‡ï¼šCA125ã€€403ï¼ŒCa153ã€€63.8ï¼ŒCa199 96.8ï¼ŒCa724 695è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.12.29ï¼‰ï¼šCA19-9:229.00U/mlâ†‘,CA125:933.00U/mlâ†‘,CA15-3:86.00U/mlâ†‘,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/Lâ†‘,ROMA:41.02%(ç»ç»å‰)â†‘,ROMA.:85.98%(ç»ç»å)â†‘ã€‚MRï¼ˆ2022.12.30ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚CTï¼ˆ2022.12.30ï¼‰ï¼šè‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚å’¨è¯¢æŠ¥å‘Š</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;High-grade adenocarcinoma involving full-thickness intestinal wall&quot;,&quot;Lymph node metastasis (4/15)&quot;,&quot;Peritoneal/rectal/vaginal involvement described&quot;],&quot;histology&quot;:&quot;é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;åµå·¢ç™Œå¤å‘&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;ç™½ç´«+å¡é“‚&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;Rise in CA125/CA19-9 on 2022-10-12&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery performed&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising tumor markers&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;6 cycles of ç™½ç´«+å¡é“‚, last 2022-08-17&quot;,&quot;last_admin_date&quot;:&quot;2022-08-17&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;Tumor size ~7x4x2.5 cm&quot;,&quot;Bilateral margins negative&quot;,&quot;Pericolic lymph nodes 4/15 positive&quot;,&quot;One tumor nodule (posterior bladder)&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;partial+&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;few weak+&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;+/-&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;60%+&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;focal+&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;-&quot;}],&quot;involvement_sites&quot;:[&quot;Rectosigmoid colon&quot;,&quot;Left retroperitoneum&quot;,&quot;Vagina&quot;,&quot;Pericolic lymph nodes&quot;,&quot;Posterior bladder nodule&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562 2022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7 x 4 x 2.5 cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;BRCA/HRD testing not reported&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules&quot;],&quot;impression&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple intrahepatic nodules, some new compared to prior&quot;],&quot;impression&quot;:&quot;Probable metastases in liver&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis; sacrum; right iliac bone&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar&quot;],&quot;impression&quot;:&quot;Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver; spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct&quot;],&quot;impression&quot;:&quot;Progression of hepatic metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: 350
- name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶
- Reason: Patient has recurrent/metastatic ovarian clear cell carcinoma (gynecologic malignancy) with prior standard therapy failure (platinum-resistant after 1L), matching the trial&#x27;s inclusion for recurrent/metastatic gynecologic malignancies after standard treatment failure.
- Missing eligibility confirmations (0-2 items):
  - ECOG performance status confirmation
  - Adequate organ function (hematologic, hepatic, renal) confirmation</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (&lt;6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 daysâ€”agree platinum-resistant classification; my initial statement was imprecise.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;â€¢ **Platinum-resistant** (PFI 56 days) clear cell carcinoma with hepatic/bone metastases; non-platinum regimen indicated [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\nâ€¢ **BRCA1/2 negative, HRD negative** [@OH2203828 | Genomics]; PARPi unlikely beneficial per clear cell carcinoma biology [@pubmed | 35096598]\n\nâ€¢ **ATM germline variant** detected; clinical significance for targeted therapy uncertainâ€”consider clinical trial enrollment or immunotherapy-based approach&quot;,
  &quot;oncologist&quot;: &quot;â€¢ Recurrent clear cell carcinoma ~5 months post-platinum; platinum-sensitive relapse warrants platinum-based rechallenge consideration [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\n\nâ€¢ ATM germline variant detected, BRCA1/2 negative, HRD negativeâ€”limited PARPi benefit expected for this histotype [@OH2203828 | Genomics] [@pubmed | 35096598]\n\nâ€¢ Hemoglobin 74 g/L indicates moderate anemia requiring correction before systemic therapy initiation [@20230103|5600862 | LAB]&quot;,
  &quot;radiologist&quot;: &quot;â€¢ Presacral mass enlarged (53Ã—44mm) with sacral/iliac bone involvement; disease progression confirmed [@2022-12-29 | MR]\n\nâ€¢ Hepatic metastases increased in number/size; splenic infarct possible [@2022-12-29 | CT]\n\nâ€¢ Imaging shows multi-site progression; assess surgical candidacy per recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]&quot;,
  &quot;pathologist&quot;: &quot;â€¢ Histology confirms ovarian clear cell carcinoma with high-grade features, HNF1B+/NapsinA focal+/WT1-, consistent with diagnosis [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]\n\nâ€¢ BRCA1/2 negative, HRD negative per NGS; ATM germline variant (p.Y316C) detectedâ€”clinical significance uncertain [@OH2203828 | Genomics]\n\nâ€¢ Clear cell histotype shows low HRR mutation prevalence, limiting PARP inhibitor benefit expectation [@pubmed | 35096598]&quot;,
  &quot;nuclear&quot;: &quot;â€¢ No PET-CT available; metabolic staging incomplete for assessing recurrence extent or treatment response monitoring.\n\nâ€¢ CT/MR show progressive hepatic metastases and presacral disease with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].\n\nâ€¢ PET-CT recommended to evaluate full metabolic burden before considering secondary cytoreduction candidacy [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;â€¢ **Non-platinum regimen required**: PFI 56 days confirms platinum-resistant status; avoid platinum rechallenge [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\nâ€¢ **Correct anemia** (Hgb 74 g/L) [@20230103|5600862 | LAB] before initiating systemic therapy; consider transfusion or erythropoietin\n\nâ€¢ **Clinical trial/immunotherapy consideration** given BRCA1/2-negative, HRD-negative status [@OH2203828 | Genomics] and limited PARPi benefit in clear cell histology&quot;,
    &quot;oncologist&quot;: &quot;â€¢ Platinum-resistant disease (PFI 56 days) requires non-platinum systemic regimen per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\nâ€¢ Correct anemia (Hgb 74 g/L) prior to therapy initiation; transfusion or iron supplementation indicated [@20230103|5600862 | LAB]\n\nâ€¢ HRD-negative, BRCA-negative status limits PARPi benefit; consider clinical trial or immunotherapy-based approach [@OH2203828 | Genomics] [@pubmed | 35096598]&quot;,
    &quot;radiologist&quot;: &quot;â€¢ Multi-site progression confirmed: presacral mass, hepatic/bone metastases; recommend PET-CT for complete staging [@2022-12-29 | MR] [@2022-12-29 | CT]\n\nâ€¢ Bone involvement (sacrum, right iliac) warrants orthopedic assessment for fracture risk before therapy initiation\n\nâ€¢ Secondary cytoreduction candidacy should be evaluated per ESMO recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]&quot;,
    &quot;pathologist&quot;: &quot;â€¢ Confirmed clear cell carcinoma, BRCA1/2 negative, HRD negative; ATM germline variant significance uncertain [@OH2203828 | Genomics]\n\nâ€¢ Low HRR mutation prevalence in clear cell histotype limits PARPi utility; consider immunotherapy/trial-based approaches [@pubmed | 35096598]\n\nâ€¢ MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy&quot;,
    &quot;nuclear&quot;: &quot;â€¢ PET-CT recommended for complete metabolic staging before treatment decisions in recurrent disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].\n\nâ€¢ Current MR/CT confirm progressive presacral and hepatic metastases with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].\n\nâ€¢ Metabolic imaging essential to assess full disease burden and monitor non-platinum therapy response.&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|10100203&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;æ€»èƒ†çº¢ç´  8.1 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 3.2 U/L (GLDH)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 34 U/L (GGT)\nå°¿ç´  4.24 mmol/l (UREA)\nç™½è›‹ç™½ 39.1 g/l (ALB)\næ€»è›‹ç™½ 70.4 g/l (TP)\nè°·è‰åŒå·¥é…¶ 7.3 U/L (ASTM)\nçƒè›‹ç™½ 31.3 g/l (GELO)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 26.5 U/L (AST)\nå°¿é…¸ 190 umol/l (UA)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.17 mmol/L (NEFA)\nç¢±æ€§ç£·é…¸é…¶ 109.4 U/L (ALP)\nå‰ç™½è›‹ç™½ 106 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  4.0 umol/L (IBIL)\nç›´æ¥èƒ†çº¢ç´  4.1 umol/l (DBIL)\nä¹³é…¸è„±æ°¢é…¶ 258 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 23.1 U/l (ALT)\nè‚Œé… 54 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.25 nan (A/G)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|10100203&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;æ€»èƒ†çº¢ç´  8.1 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 3.2 U/L (GLDH)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 34 U/L (GGT)\nå°¿ç´  4.24 mmol/l (UREA)\nç™½è›‹ç™½ 39.1 g/l (ALB)\næ€»è›‹ç™½ 70.4 g/l (TP)\nè°·è‰åŒå·¥é…¶ 7.3 U/L (ASTM)\nçƒè›‹ç™½ 31.3 g/l (GELO)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 26.5 U/L (AST)\nå°¿é…¸ 190 umol/l (UA)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.17 mmol/L (NEFA)\nç¢±æ€§ç£·é…¸é…¶ 109.4 U/L (ALP)\nå‰ç™½è›‹ç™½ 106 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  4.0 umol/L (IBIL)\nç›´æ¥èƒ†çº¢ç´  4.1 umol/l (DBIL)\nä¹³é…¸è„±æ°¢é…¶ 258 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 23.1 U/l (ALT)\nè‚Œé… 54 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.25 nan (A/G)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Recurrent ovarian clear cell carcinoma, platinum-resistant (relapse &lt;6 months post-chemotherapy), with hepatic, pelvic, and possible bone metastases; HRD-negative, BRCA1/2-negative, germline ATM Y316C variant; MSS; Ki-67 60%; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6633 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 8] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]
    cancer will relapse within 3 years. Relapse rates for early- stage ovarian cancer are much lower. Several factors need to be assessed when selecting a treatment for patients with recurrent disease (Figure 3). Systemic therapy of recurrent disease is based on plat- inum-containing or non-platinum-conâ€¦
[2] score=0.6590 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 11] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
    cytoreduction o Residual ChT toxicity o The patientâ€™s general condition and preferences  Patients with ï¬rst relapse of ovarian cancer after &gt;6 months of last platinum administration should be evalu- ated by a gynaecological oncology centre experienced in surgery for ovarian cancer to identify potenâ€¦
[3] score=0.6562 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]
    with ï¬rst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected â€¦
[4] score=0.6520 nccn_ovariancancer_v3_2025__v00000000 [PAGE 22] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
    Survivorship) Recurrent diseaset Hormonal therapyu or Chemotherapy (if not previously used), see OV-C (6 of 12) or Systemic therapyf,v â€¢ For platinum-sensitive disease, see OV-C (8 of 12) â€¢ For platinum-resistant disease, see OV-C (9 of 12) or Observation f See Principles of Systemic Therapy (OV-C) â€¦
[5] score=0.6492 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCCâ€¦

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7022 PMID 30109783 [@pubmed | 30109783]
    Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.
    NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45Â hours and form colonies at high efficiency. They have a very high degree of loss of heteroâ€¦
[2] score=0.7001 PMID 35096598 [@pubmed | 35096598]
    Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.
    Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endomeâ€¦
[3] score=0.6933 PMID 33758607 [@pubmed | 33758607]
    Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
    Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometrâ€¦
[4] score=0.6927 PMID 35356229 [@pubmed | 35356229]
    Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor.
    Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CAâ€¦
[5] score=0.6909 PMID 35401005 [@pubmed | 35401005]
    Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.
    Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. Theâ€¦</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6632776856422424,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;cancer will relapse within 3 years. Relapse rates for early-\nstage ovarian cancer are much lower.\nSeveral factors need to be assessed when selecting a\ntreatment for patients with recurrent disease (Figure 3).\nSystemic therapy of recurrent disease is based on plat-\ninum-containing\nor\nnon-platinum-containing\nregimens.\nThere are currently no molecular biomarkers to predict ef-\nï¬cacy of platinum rechallenge. The deï¬nition of platinum\nsensitivity based on a 6-month cut-off of treatment-free\ninterval from last platinum (TFIp) was challenged during\nthe Fifth Gynecological Cancer InterGroup (GCIG) Ovarian\nCancer Consensus Conference and later discontinued in\nclinical practice following the 2018 ESMOeEuropean Soci-\nety of Gynaecological Oncology (ESGO) Consensus Confer-\nence, as many factors may inï¬‚uence TFIp (e.g. the\nfrequency of follow-up and interval of diagnostic tests) and\nthe response to platinum (i.e. histotype or BRCA1/2-mut\nstatus).32,66 Not all patients with TFIp &gt;6 months respond\nto platinum (objective response rate 47.2%-66%),32 and\nconversely, platinum-based combinations have demon-\nstrated activity in patients with TFIp &lt;6 months.67\nSurgery for relapse&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6590089201927185,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;cytoreduction\no Residual ChT toxicity\no The patientâ€™s general condition and preferences\n\u0004 Patients with ï¬rst relapse of ovarian cancer after &gt;6\nmonths of last platinum administration should be evalu-\nated by a gynaecological oncology centre experienced in\nsurgery for ovarian cancer to identify potential candi-\ndates for surgical cytoreduction [I, A].\n\u0004 Patients who have previously responded to platinum\nwithout early symptomatic relapse should be treated\nwith either a platinum-based doublet (PLD, gemcitabine\nor paclitaxel) with bevacizumab [I, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3]\nor a platinum-based doublet followed by maintenance\nwith PARPi therapy if a response is achieved and the\npatient has not been previously exposed to PARPis\n[I, A; olaparib for BRCA1/2-mutated: ESMO-MCBS v1.1\nscore: 2; niraparib regardless of BRCA1/2-mut status:\nESMO-MCBS v1.1 score: 3; rucaparib regardless of\nBRCA1/2-mut status: ESMO-MCBS v1.1 score: 3].\n\u0004 For patients requiring rapid response, the combination\nof a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6562480926513672,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ï¬rst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciï¬cally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6520251035690308,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 22,
    &quot;text&quot;: &quot;Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\nâ€¢ For platinum-sensitive disease, see OV-C (8 of 12)\nâ€¢ For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRÎ± (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6492393016815186,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\nâ€¢ Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n â—ŠIf not previously used (category 1)\n â—ŠIf disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.7021940461962418,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;30109783&quot;,
    &quot;title&quot;: &quot;Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.&quot;,
    &quot;abstract&quot;: &quot;NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45Â hours and form colonies at high efficiency. They have a very high degree of loss of heterozygosity (LOH) affecting approximately 85% of the genome, mostly copy neutral and almost identical to the original tumor. The cells express epithelial (pan-cytokeratin) and mesenchymal (vimentin) characteristics, CA125 and p16, like the original tumor. They also express ARID1A but not HNF-1Î² and, like the original tumor, and are negative for p53 expression, with no evidence of p53 function. NUCOLL43 cells express all other DNA damage response proteins investigated and have functional homologous recombination DNA repair. They are insensitive to cisplatin, the PARP inhibitor rucaparib, and MDM2 inhibitors but are sensitive to camptothecin, paclitaxel, and NVP-BEZ235. The NUCOLL43 cell line represents a distinct subtype of O-CCC that is p53 and HNF-1Î² null but expresses ARID1A. Its high degree of similarity with the original tumor genomically and proteomically, as well as the high level of LOH, make this an interesting cell line for O-CCC research. It has been deposited with Ximbio.&quot;,
    &quot;journal&quot;: &quot;Cancer Med&quot;,
    &quot;pub_date&quot;: &quot;2018-09-01&quot;,
    &quot;doi&quot;: &quot;10.1002/cam4.1724&quot;,
    &quot;impact_factor&quot;: 3.1,
    &quot;similarity&quot;: 0.7021940461962418
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.700080908481534,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35096598&quot;,
    &quot;title&quot;: &quot;Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endometrial carcinoma (EC) is potentially applicable in OCCC. In this study, surgically resected samples were collected from 44 patients with OCCC. Genomic alterations were determined using next-generation sequencing. HRD was estimated by genomic instability. Of 44 patients with OCCC, two (4.5%) harbored likely pathogenic mutations in HRR genes. Notably, no pathogenic or likely pathogenic mutations were found in BRCA1/2. A total of 24 variants of uncertain significance (VUS) in HRR-related genes occurred in 18 (40.9%) patients. HRD was observed in only one case (2.3%). In addition, TP53 mutation and microsatellite instability-high (MSI-H) were identified in three patients (6.8%) and in one patient (2.3%), respectively. TP53 mutation was significantly associated with disease-free survival and overall survival. No POLE mutations were found. In conclusion, our results revealed a very low prevalence of HRR gene mutations and HRD in OCCC. Moreover, TP53 mutations and MSI-H are uncommon, while POLE mutations are extremely rare in OCCC. Our findings indicate that the evaluation of HRR gene mutations, HRD status, POLE mutations, and MSI-H may have limited clinical significance for OCCC treatment and prognostic stratification.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2021.798173&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.700080908481534
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6933309006212954,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33758607&quot;,
    &quot;title&quot;: &quot;Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometrioid carcinoma, which also originates from endometriosis, shares several features with OCCC, including platinum resistance and younger age at diagnosis. Patients with OCCC have about a 2.5 to 4 times greater risk of having a venous thromboembolism (VTE) compared with other EOC, and OCCC tends to metastasize through lymphatic vesicular and peritoneal spread as opposed to hematogenous metastasis. There is only mild elevation of the conventional biomarker CA125. Staging surgery or optimal cytoreduction combined with chemotherapy is a common therapeutic strategy for OCCC. However, platinum resistance commonly portends a poor prognosis, so novel treatments are urgently needed. Targeted therapy and immunotherapy are currently being studied, including PARP, EZH2, and ATR inhibitors combined with the synthetic lethality of ARID1A-dificiency, and MAPK/PI3K/HER2, VEGF/bFGF/PDGF, HNF1Î², and PD-1/PD-L1 inhibitors. Advanced stage, suboptimal cytoreduction, platinum resistance, lymph node metastasis, and VTE are major prognostic predictors for OCCC. We focus on update pathogenesis, diagnostic methods and therapeutic approaches to provide future directions for clinical diagnosis and treatment of OCCC.&quot;,
    &quot;journal&quot;: &quot;J Cancer&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.7150/jca.53395&quot;,
    &quot;impact_factor&quot;: 3.2,
    &quot;similarity&quot;: 0.6933309006212954
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6926693215161032,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35356229&quot;,
    &quot;title&quot;: &quot;Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor.&quot;,
    &quot;abstract&quot;: &quot;Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) &gt;10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2022.789228&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.6926693215161032
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6908852650678853,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35401005&quot;,
    &quot;title&quot;: &quot;Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The patient received primary cytoreductive surgery with adjuvant chemotherapy and remained disease-free for four months. She then experienced retroperitoneal lymph node recurrence and was treated with liposomal doxorubicin chemotherapy followed by secondary debulking surgery. The patient experienced a second relapse in the lower left lung 11 months later. Genomic profiling of tumor samples revealed a deleterious AT-rich interactive domain 1A (ARID1A) mutation and homologous recombination deficiency. Thus, the triplet combination of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib; the PD-1 inhibitor, pembrolizumab; and the antiangiogenic agent, bevacizumab was administered. The patient achieved partial response, which was sustained for 12 months. Our study provides the first clinical evidence that the combination of olaparib with pembrolizumab and bevacizumab could be an effective treatment for patients with platinum-resistant, recurrent OCCC.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S362267&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.6908852650678853
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>- Majority of advanced ovarian cancers relapse within 3 years; treatment selection for recurrent disease requires assessment of multiple factors including platinum sensitivity and prior therapies [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]

- Patients with first relapse &gt;6 months after last platinum should be evaluated by a gynecological oncology center experienced in ovarian cancer surgery to assess candidacy for secondary cytoreduction [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]

- Selection of PARPi or anti-VEGF therapy in relapse should consider histotype, BRCA1/2 mutation status, prior therapies (including prior PARPi and/or bevacizumab), and expected toxicity from cumulative platinum exposure [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]

- For recurrent disease, treatment options are stratified by platinum sensitivity: platinum-sensitive disease and platinum-resistant disease have distinct recommended systemic therapy pathways [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

- For first recurrence, platinum-based chemotherapy is preferred (category 1); secondary cytoreductive surgery should be considered with immediate platinum-based recurrence therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]

- Ovarian clear cell carcinoma cell lines demonstrate high loss of heterozygosity and specific drug sensitivity profiles that may inform treatment selection [@pubmed | 30109783]

- Next-generation sequencing shows very low prevalence of HRR gene mutations and homologous recombination deficiency in ovarian clear cell carcinoma, suggesting limited benefit from PARP inhibitors in this histotype [@pubmed | 35096598]

- Ovarian clear cell carcinoma is a distinct histological subtype with high Asian prevalence, association with endometriosis, and lacks specific molecular subtype classification for targeted therapy [@pubmed | 33758607]

- PD-1 inhibitors may have activity in recurrent ovarian squamous cell carcinoma with specific mutations such as PIK3CA, suggesting potential immunotherapy role in select cases [@pubmed | 35356229]

- Triplet combination of olaparib with pembrolizumab and bevacizumab showed remarkable response in third-line treatment of recurrent OCCC with ARID1A mutation, suggesting potential efficacy in molecularly selected patients [@pubmed | 35401005]</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:07.509814&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:07.510273&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;2a31f255c155&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:07.801476&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:18.090863&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|10100203|2023-01-03&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|10100203|2023-01-03&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:18.096595&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=åµå·¢ç™Œå¤å‘; histology=é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:46.257035&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Recurrent ovarian clear cell carcinoma, platinum-resistant (relapse &lt;6 months post-chemotherapy), with hepatic, pelvic, and possible bone metastases; HRD-negative, BRCA1/2-negative, germline ATM Y316C variant; MSS; Ki-67 60%; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:46.257040&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:46.257042&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:12:46.257044&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:00.679598&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:00.679673&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:08.332232&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 482
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:08.332293&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:15.630544&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 484
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:15.630653&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:22.112890&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 371
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:22.112977&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:29.261824&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 457
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:29.261928&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:34.534406&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 421
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:13:50.120505&quot;,
    &quot;event&quot;: &quot;evidence_tag_warning&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist-&gt;chair/turn_1&quot;,
      &quot;preview&quot;: &quot;Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 daysâ€”agree platinum-resistant classificâ€¦&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:14:30.509872&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2007
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:14:30.511781&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:14:38.530678&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: true
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:14:38.530698&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:14:45.921042&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 2561
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
